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MigrationThe effect of transplantation dose on the spatiotemporal dynamics of human neural stem cell (hNSC) engraftment
has not been quantitatively evaluated in the central nervous system.We investigated changes over time in engraft-
ment/survival, proliferation, andmigration ofmultipotent human central nervous system-derived neural stem cells
(hCNS-SCns) transplanted at doses ranging from 10,000 to 500,000 cells in spinal cord injured immunodeﬁcient
mice. Transplant dose was inversely correlated with measures of donor cell proliferation at 2 weeks post-
transplant (WPT) and dose-normalized engraftment at 16WPT. Critically, mice receiving the highest cell dose ex-
hibited an engraftment plateau, inwhich the total number of engrafted human cells never exceeded the initial dose.
These data suggest that donor cell expansionwas inversely regulated by target niche parameters and/or transplan-
tation density. Investigation of the response of donor cells to the hostmicroenvironment should be a key variable in
deﬁning target cell dose in pre-clinical models of CNS disease and injury.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
We have previously shown that human central nervous system-
derived stem cells propagated as neurospheres (hCNS-SCns) (Uchida
et al., 2000) exhibit robust engraftment in the injured spinal cord niche
after transplantation at acute, sub-acute or chronic stages of injury in
immunodeﬁcient rodent models (Cummings et al., 2005; Hooshmand
et al., 2009; Salazar et al., 2010; Piltti et al., 2013a,b). Further, when
transplanted into an immunodeﬁcient model in which rejection of the
xenograft is minimized, human cells were capable of both prolifera-
tion and extensive migration (Anderson et al., 2011), both of which are
normal processes for CNS development (Lui et al., 2011; Hatten, 1999;
Wilcock et al., 2007). In theseparadigms, recovery of functionwasdirectly
dependent on, and linearly correlated with, hCNS-SCns survival and en-
graftment, suggesting that integration with the host microenvironment
is critical.Center, University of California
ss article under the CC BY-NC-ND licStem cell responses in the host microenvironment depend on both
intrinsic properties and extrinsic signals (Watt and Hogan, 2000; Jones
and Wagers, 2008; Discher et al., 2009; Johnston, 2009; Voog and
Jones, 2010; Wagers, 2012; Faigle and Song, 2013). Understanding the
dynamics of donor cell engraftment, proliferation and migration is im-
portant for optimizing cell therapies for the injured or diseased CNS.
Our recent data indicates that the spinal cord injury (SCI)microenviron-
ment alters the dynamics of transplanted hCNS-SCnswhen compared to
that in uninjured SCI models, suggesting that injury-induced cues and
target niche availability play a role in donor cellmaturation andmigration
(Sontag et al., 2014). Additionally, donor cellsmay also secrete factors that
serve as extrinsic cues in a dose or density dependent manner. While it is
has generally been assumed that ‘more is better’ in the context of pre-
clinical stem cell transplantation, the capacity of the CNS niche to accom-
modate or provide cues for donor cell integration is unclear. Few studies
have investigated the effect of unmodiﬁed human neural stem cell
(hNSC) dose in CNS injury or disease models (Ostenfeld et al., 2000;
Keirstead et al., 2005; Rossi et al., 2010; Darsalia et al., 2011). Further,
none of these studies quantitatively investigated the effect of transplanta-
tion dose on the spatiotemporal dynamics of engraftment, or employed a
model in which human cell rejection was sufﬁciently suppressed to per-
mit donor cell expansion (Anderson et al., 2011). Accordingly, in thisense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and early and long-term cell survival, proliferation, and migration as
determined by unbiased stereological assessment of donor cells in the
injured spinal cord of immunodeﬁcient NOD-scidmice at 2 days post-
transplantation (2 DPT), 2 weeks post-transplantation (WPT) and 16
WPT.
2. Materials and methods
2.1. Ethics statement
This study was carried out in accordance with Institutional Animal
Care andUse Committee regulations at theUniversity of California, Irvine.
2.2. hNSC isolation and culture
hCNS-SCns derivation, culture and characterization were as described
(Uchida et al., 2000). Methods and lines used in this study are identical to
those described in Cummings et al. (2005), Salazar et al. (2010), and Piltti
et al. (2013a,b). Brieﬂy, hCNS-SCns were propagated as neurospheres in
X-Vivo 15 medium without phenol red (Lonza, Basel, Switzerland)
supplemented with N2, bFGF, EGF, heparin, NAC, and LIF as described
previously (Uchida et al., 2000; Cummings et al., 2005). Prior to transplan-
tation, cells (passage ≤12) were dissociated into single cells and adjusted
to the following densities: 10,000 (low dose), 100,000 (medium dose),
250,000 (high dose) or 500,000 (very high dose) cells per 5 μl in X-Vivo
15. The highest employed cell dose was selected based on the maximum
injection volume at which neither tissue damage or behavioral deﬁcits
were observed in uninjuredmice as empirically determined in pilot stud-
ies (1.25 μl/site); maximum cell packaging density was calculated based
on hCNS-SCns size (100,000 cells/μl). Viability of hCNS-SCns after pre-
transplantation cell prep and at the end of transplantation day (8–10 h
post-cell prep) was N90% (Table S1B).
2.3. Contusion injuries and cell transplantation
Contusion SCI was followed by early chronic hCNS-SCns transplanta-
tion into the intact parenchyma, performed as described previously
(Cummings et al., 2005; Salazar et al., 2010). Brieﬂy, adult female NOD-
scidmice (Jackson Laboratory, Sacramento, CA) were anesthetized with
isoﬂurane (VetEquip Inc., Pleasanton, CA), received a T9 laminectomy
using a surgical microscope, and a bilateral 50-kDa contusion injury
using the Inﬁnite Horizon Impactor (Precision Systems and Instrumenta-
tion, Lexington, KY). 30 d post-SCI, mice were re-anesthetized and 1.25 μl
of freshly triturated hCNS-SCns suspension injected at four bilateral sites
(for a total of 5 μl) 0.75 mm from midline. Two injection sites were at
the posterior aspect of T8 (rostral to the site of injury), and two at the an-
terior aspect of T10 (caudal to the site of injury). Injectionswere conduct-
ed using a Nanoinjector with a micro controller (World Precision
Instruments, Waltham, MA) at speed of 417 nl/min, followed by a 2 m
delay before withdrawal of the needle, using pulled silicon-treated glass
injection tips with a 70 μm ID and 110 μmOD (Sutter Instruments, Nova-
to, CA). For assessing hCNS-SCns proliferation at 2DPT or 2WPT, themice
were injected i.p. with 50mg/kg of BrdU (AbD Serotec, Raleigh, NC) every
12 h starting from the time of transplantation until 2 DPT or 2 WPT.
2.4. Randomization, exclusion criteria, and group numbers
Randomization for group allocation, exclusion criteria, and
blinding for histological analysis were conducted as described previously
(Cummings et al., 2005; Hooshmand et al., 2009; Salazar et al., 2010).
Animals with unilateral bruising or abnormal force/displacement curves
after contusion injury, or with a surgical note of poor initial injection
due to imperfect needle penetration or back-ﬂow during injection (by
blinded surgeon) were excluded from stereological assessments (for ex-
clusions see Fig. 1A). All dose groups in each time cohortswere conductedin parallel, that is, animals received spinal cord injuries at the same age
and during the same week of surgery. All animal care, and histological
processing/analysis were performed by observers blinded to experimen-
tal cohorts or groups. Final group numbers used in histological analysis
are listed in Fig. 1A.
2.5. Perfusion, tissue collection, tissue sectioning and immunohistochemistry
Endpoints for assessing the dynamics of hCNS-SCns survival, prolifer-
ation and engraftment were selected based on our previous study de-
scribing the effect of SCI niche on hCNS-SCns engraftment between 1
DPT and 14 WPT (Sontag et al., 2014). Accordingly, the selected times
represent the phases of early engraftment, proliferative expansion in
the SCI niche, and the time at which the majority of donor cells have
exited the cell cycle and differentiated. Mice were anesthetized and
transcardially perfused 2DPT, 2WPT, and 16WPTwith 4% paraformalde-
hyde. The spinal cord T6–T12 segments were dissected based on dorsal
spinal root counts, postﬁxed in 20% sucrose/4% paraformaldehyde over-
night and frozen in isopentane at −65 °C. For brightﬁeld stereology,
T6–T12 segments were sectioned at 30 μm coronally using a CryoJane
tape transfer system (LeicaMicrosystems Inc., Buffalo Grove, IL). Sections
were processed for antigen retrieval using Buffer A (pH = 6) in the Re-
triever 2100 system (PickCell Laboratories, Amsterdam, Netherlands).
For ﬂuorescence conjugated immunohistochemistry, T6–T12 segments
were sectioned at 30 μm coronally using a HM 450 microtome
(ThermoScientiﬁc, Fairlawn, NJ). 2 DPT and 2 WPT cohort T6–T12 spinal
segmentswere trimmed rostrally and caudally 4mm from the injury epi-
center before sectioning. Antibodies and dilutions used are listed in
Fig. 1B.
2.6. Stereological analysis
Unbiased stereology was conducted using systematic random
sampling with the optical fractionator probe, and StereoInvestigator ver-
sion 9 (Micro BrightField Inc., Williston, VT). Parameters for the analysis
are listed in Table S2. Fluorescence immunostained sections were ana-
lyzed from Z-stacks of 15 μm thick optical slices captured in 1 μm inter-
vals using an ApoTome microscope (Zeiss, Maple Grove, MN) and 63×
objective.
2.7. Cell migration analysis
For rostral–caudal proportional migration analysis, the number of
stereologically quantiﬁed human cells located in the rostral versus caudal
regions of spinal cordwas compared after the sections in each spinal cord
were aligned by injury epicenter, designated by themost damaged tissue
section with the largest cross sectional lesion area. Maximal distance of
cellmigration (cell spread rostral and caudal relative to the injury epicen-
ter) was determined by the distance between ﬁrst and last spinal cord
section with SC121+ cells visualized using an inverted microscope
(IX71, Olympus, Center Valley, PA).
2.8. Statistical analysis
All data are shown asmean± standard error of mean (SEM). Statisti-
cal analysiswas performed using Prism4 software, version 5.0 (GraphPad
Software, San Diego, CA). Correlation between transplant dose and total
number engrafted cells, survival/expansion, and migration/localization
were assessed using Pearson correlation coefﬁcient and linear regression
analyses. Comparison of estimated total cell numbers, survival and
expansion, maximal rostral–caudal migration distance, mitotic index,
and proportion of apoptotic CC3+, BrdU+ or Ki67+ human cells between
the groups were analyzed either with one-way analysis of variance
(1-way ANOVA) combined with Tukey's post hoc t-test, or Student's
2-tailed t-test. A p value ≤0.05 was considered to be statistically
signiﬁcant.
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Fig. 1. Exclusions, ﬁnal group numbers, and antibodies used in the study. (A) Group Ns (purple boxes) and exclusions (gray boxes) of the animals entering the study. Of note thymomas
and other health complications increase dramatically with age in NOD-scid animals (Prochazka et al., 1992), resulting in an average lifespan of ~7 months of age, and a relatively high
exclusion rate in the delayed transplantation paradigm employed here. Additionally, all animals were carefully screened before the study. Exclusions based on physiological phenotypes
and not surgical, health, or other complications are described below for completeness (not included in A). Two physiological phenotypes resulted in a large number of exclusions. First,
animals with a physical defect, such as tail malformation ormissing toe (n= 2). Second, a proportion of mice (n= 19) exhibited stereotyped behavioral events consistent with a seizure
disorder during handling. Events resulting in exclusion included freezing and facial movements characteristic of Racine Stage 1. The phenotype was not speciﬁc to either surgery or transplan-
tation; however, because the potential effect of these events on transplanted cells is unknown, all mice received additional monitoring, and any animals in which repeated events (N 4) were
observedwere excluded from the study (n=10). (B) Antibodies anddilutions used for DABorﬂuorescence immunohistochemistry.Mayer's hematoxylin solution (Sigma-Aldrich) orHoechst
33342 (Invitrogen) was used for nuclear labeling.
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3.1. hCNS-SCns engraftment and apoptosis 2 days post-transplant (DPT),
2 weeks post-transplant (WPT) and 16 WPT
hCNS-SCns transplanted in the early chronic stage 30 days post-SCI
at doses of 10,000 (low), 100,000 (medium), 250,000 (high) or
500,000 cells (very high) exhibited robust engraftment in NOD-scid
mice (Fig. 2A). 94.2% of all transplanted mice (n = 49/52 animals)
showed engraftment of human cells, based on immunohistochemistry
for the human-speciﬁc cytoplasmic marker SC121 (Fig. 2A). One animal
in the low dose group and another in the medium dose group in the 16
WPT cohort showed no engraftment, whichmay have been due to failure
during the transplant injection; these animals were excluded fromfurther analysis. Cohort and group numbers for stereological analysis
were as described in Materials and methods and in Fig. 1A. Detailed
histological analysis of spinal cord tissue showed no evidence of tumor
formation in any dose groups at any time points.
Based on our earlier data, hCNS-SC engraftment is not remarkably
changed by proliferation or cell death within the ﬁrst week post-
transplantation (Sontag et al., 2014). To assess relationships between
hCNS-SCns dose and human cell integration in the injured spinal cord,
we carried out unbiased stereological analysis of the total numbers of
SC121+ human cells at 2 WPT and 16 WPT. At 2 WPT, the estimated
numbers of hCNS-SCns ranged from 2877 cells in the low dose group
to 44,215 cells in the very high dose group (Fig. 2B, colored bars).
hCNS-SCns number increased signiﬁcantly, andwas positively correlated
with transplant dose (Fig. S1A, Pearson r = 0.74, ***p ≤ 0.0003). In
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Fig. 2. Transplantation of hCNS-SCns at early chronic stage of SCI results in linear engraftment in relation to the initial transplantation dose. (A) An example of a coronal spinal cord section
in each dose group after immunostaining for the human speciﬁc cytoplasmicmarker SC121 (brownDAB) and hematoxylin. Scale bars 300 μm(lowmag) and 50 μm(highmag). Estimated
total number of hCNS-SCns positive for SC121 (bars shaded to indicate dose) were signiﬁcantly greater in the very high dose group when compared to the low or medium dose groups
(B) at 2WPT or (C) 16WPT;mean±SEM, 1-wayANOVA p=0.009 (previously published in Piltti et al., submitted for publication) and 1-wayANOVA p=0.0002, respectively. Tukey's t-test
p values are shown in the graphs. (D) Comparative analysis revealed no signiﬁcant improvement in goodness of ﬁt when a second order polynomial versus a ﬁrst order linear ﬁt was applied
to the data set at 2 WPT; Extra Sum of Squares F test p ≤ 0.79, n= 3/group. However, (E) a signiﬁcant improvement in goodness of ﬁt when a second order polynomial versus a ﬁrst order
linear ﬁt was applied to the data set containing all dose groups, suggesting an engraftment plateau at 16WPT; Extra Sum of Squares F test p ≤ 0.02, n=5/group. (F) This was not apparent
when the very high dose groupwas eliminated from the 16WPT dataset; p ≤ 0.96, n=5/group (previously published in Piltti et al., submitted for publication). 2WPT cohort n=3 animals/
group, 16 WPT cohort n= 5 animals/group.
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46,932 cells in the low dose group to 423,554 cells in the very high
dose group (Fig. 2C). Again, hCNS-SCns number increased signiﬁcantly,
and was positively correlated with transplant dose (Fig. S1B, Pearson
r = 0.74, ***p ≤ 0.0002). These data suggest that the total number of
human cells in the injured spinal cord is linearly related to the initial
transplantation dose. However, the number of human cells present at
16WPT appeared to plateau at higher doses (Fig. 2C). Comparative anal-
ysis revealed a signiﬁcant improvement in goodness of ﬁt when a second
order polynomial versus a ﬁrst order linear ﬁt was applied to the data set
containing all dose groups (Fig. 2E; Extra Sum of Squares F test p ≤ 0.02),
which was not apparent at 2 WPT (Fig. 2D; Extra Sum of Squares F test
p ≤ 0.79) or when the very high dose group was eliminated from the 16WPT dataset (Fig. 2F; Extra Sum of Squares F test p ≤ 0.96). These data
support a change in engraftment dynamics between the ‘high’ and
‘very’ high dose groups, resulting in an engraftment plateau between 2
WPT and 16 WPT. Finally, the low number of surviving donor cells at 2
WPT indicates that a large fraction of the initial transplant was lost, as
previously reported.
3.2. hCNS-SCns survival and expansion between 2 and 16 WPT
To assess early hCNS-SCns survival, we conducted double-labeling
immunohistochemistry for SC121 and the apoptotic marker cleaved
caspase 3 (CC3) at 2 days post-transplantation (DPT), 2 weeks post-
transplantation (WPT) and 16 WPT, as illustrated in Fig. 3A. Apoptosis
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Fig. 3. Transplant dose does not alter early cell survival but has an inverse effect long term on donor cell survival/expansion (16WPT). (A) An example of spinal cord sections immunostained
for SC121 and cleaved caspase-3 (CC3) showing that few human cells were undergoing apoptosis (arrows) at 2 DPT or 16WPT. Scale bars 300 μm (lowmag) and 20 μm (high mag). (B) No
signiﬁcant differenceswere found in the proportion of SC121+/CC3+ cells between low and very high dose groups at 2DPT, 2WPT or 16WPT; Student's 2-tailed t-test p ≤ 0.4, p ≤ 0.5 or p ≤ 0.2
respectively, n=3 animals/group. hCNS-SCns cell survival and expansion rate per dose group in the injured spinal cords after the total numbers of SC121+ human cells were normalizedwith
the initial transplantationdoses at (C) 2WPTor (E) 16WPT;mean±SEM, 1-wayANOVA p=0.35; 1-wayANOVA p=0.001, respectively. Tukey's t-test p values are shown in the graph, as are
individual data points in each dose group (dots shaded to indicate dose) and the initial transplantation dose (dashed line). Correlation coefﬁcients revealed no relationship between cell dose
and survival at 2WPT (D) but there was an inverse correlation between dose and donor cell expansionmagnitude at 16WPT (F); Pearson r=−0.41, p ≤ 0.18; Pearson r=−0.63, p ≤ 0.003,
respectively. XY scatterplots data points/group (dots) and regression line ± SEM. 2 WPT cohort n= 3 animals/group, 16 WPT cohort n= 5 animals/group.
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346 K.M. Piltti et al. / Stem Cell Research 15 (2015) 341–353has been suggested to be a predominant mechanism of cell death
following neural stem cell xenotransplantation in immunosuppressed
injury models (Bakshi et al., 2005). However, in our study, very few
SC121+human cells in any dose group or timepoint assessed expressed
CC3, and no signiﬁcant differences were found between low and very
high dose groups at any time points (Fig. 3B). Critically, hCNS-SCns
survival was not signiﬁcantly decreased as a part of the process of cell
preparation for transplantation, as N90% viability is observed before
and 8–10 h post-cell preparation (Table S1B). These data therefore
suggest that hCNS-SCns loss was likely to occur shortly after or during
the transplantation process, likely as a result of mechanical shear forces
during injection (Aguado et al., 2012).
In our previous studies, hCNS-SCns transplanted at a dose of 75,000
cells exhibited an average of 250% expansion over the initial trans-
plantation dose in this immunodeﬁcient mouse SCI model by 12–16
WPT (Cummings et al., 2005; Hooshmand et al., 2009; Salazar et al.,
2010; Sontag et al., 2013, 2014). To test the effect of dose on donor cell
survival/expansion,wenormalized the stereologically quantiﬁednumber
of human cells present to the initial transplantation dose to obtain the
proportion of surviving cells at 2 and 16WPT. At 2WPT this value ranged
from 28.8% in the low dose group to 8.8% in the very high dose group. No
signiﬁcant difference was found between dose groups (Fig. 3C), and no
correlative relationship was detected between dose and survival
(Fig. 3D). In contrast, at 16 WPT signiﬁcant differences between dose
and expansion were observed. The expansion value ranged from 469%
in the low dose group to 85% in the very high dose group (Fig. 3E).
Although the very high dose group showed the greatest numbers of
SC121+ human cells, the expansion magnitude was signiﬁcantly greater
in the low dose group (Fig. 3E), and there was an inverse correlationTwo predictive models o
in host injury m
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tected at 16 WPT.between increasing dose and expansion magnitude (Fig. 3F). This obser-
vation was also true if expansionmagnitude was determined by normal-
izing the stereologically quantiﬁed number of donor cells present 16WPT
to the number of surviving donor cells present at 2 WPT. Surprisingly,
these data suggest a 15–16 fold expansion of cell number in the low, me-
dium and high dose groups (Fig. 4A). Importantly, however, while this is
a striking degree of donor cell expansion in the hostmicroenvironment, a
geometric model predicts that only four divisions of each surviving
human cell at 2WPTwould be sufﬁcient to result in the numbers detect-
ed at 16 WPT (Fig. 4B).
3.3. hCNS-SCns migration kinetics/dynamics
We have previously reported that hCNS-SCns transplantation in
NOD-scid SCI model 9 days post-injury (dpi) resulted in an equivalent
distribution of donor cells rostral and caudal to the epicenter that was
irrespective to the time of post-transplantation assessment; 1, 7, 14,
28 or 96 DPT. However, hCNS-SCns transplantation in the same SCI
model 30 dpi resulted in increased cell localization in the region rostral
to the epicenter as previously detected (Salazar et al., 2010), suggesting
that cell migration/proliferation cues within the injured tissue may
change in a time dependentmanner. 3D reconstruction of the localization
of donor cells based on stereological quantiﬁcation of the number of
SC121+ human cells at 2 WPT (14 DPT) and 16 WPT (96 DPT) revealed
a strong localization to the region rostral to the epicenter (Fig. 5A–B,
Movies S1–4). To measure the effect of transplant dose on rostral or
caudal proportional migration of donor cells, we compared the number
of stereologically quantiﬁed human cells located in the rostral versus
caudal regions of spinal cord sections aligned by the injury epicenterf hCNS-SCns proliferation 
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Fig. 5. Effect of transplant on rostral–caudal proportional migration in the injured spinal cord niche. 3D reconstructions of transplanted spinal cords illustrating the location of analyzed
SC121+ human cells (dots shaded to indicate dose) relative to the lesion area (purple shaded area) at 2WPT (A) or 16WPT (B) show a strong preference of hCNS-SCns for rostral regions
after early-chronic transplantation. At 2WPT, correlation analyses revealed no dose-dependent relationship in rostral (C), epicenter (D), or caudal (E) localization of donor cells; Pearson
r =−0.09, p ≤ 0.8; r = 0.35, p ≤ 0.3; r =−0.19, p ≤ 0.5, respectively. However, at 16 WPT, although there was no dose-dependent relationship in rostral (F) localization of donor cells,
increasing cell dose exhibited a negative correlationwith epicenter (G) localization, and a positive correlationwith caudal (H) localization, suggesting that increasing transplantation dose
increased caudal donor cell migration; Pearson r=−0.2, p ≤ 0.3; r =−0.69, p ≤ 0.002; r = 0.45, p ≤ 0.04, respectively. XY scatterplots of data points/group (colored dots) and regression
line ± SEM. 2 WPT cohort n = 3 animals/group, 16 WPT cohort n = 5 animals/group.
347K.M. Piltti et al. / Stem Cell Research 15 (2015) 341–353as designated by the most damaged tissue section with largest cross
sectional lesion area. Correlation analyses revealed no total human
cell number-dependent relationship in the rostral, epicenter, or caudal
localization of donor cells 2 WPT (Fig. 5C–E), or in rostral localization
16 WPT (Fig. 5F). In contrast, engrafted human cell number exhibited
a inverse correlationwith epicenter localization (Fig. 5G), and a positive
correlation with caudal localization (Fig. 5H) 16 WPT. These datasuggest that delayed transplantation was associated with early prefer-
ential localization of donor cells to regions rostral to the injury, and that
increasing dose in this paradigm expanded the migration of cells to cau-
dal areas by 16 WPT.
To investigate the kinetics of human cellmigration in the injured spi-
nal cord, we next asked whether donor cell dose affected maximal ros-
tral–caudal migration; that is, the distance between the farthest
348 K.M. Piltti et al. / Stem Cell Research 15 (2015) 341–353observed rostral and caudal donor cells. We expanded our analysis of
early engraftment time points to include 2 DPT, and determined the dis-
tance between the ﬁrst and last spinal cord section in which SC121+
human cells were found at 2 DPT, 2WPT and 16WPT. At 2 DPT, thema-
jority of hCNS-SCns were located near the four injection sites, and there
was a signiﬁcant increase in the maximal rostral–caudal migration of
donor human SC121+ cells in the very high versus low dose groups
(Fig. 6A). This observation was paralleled at 2 WPT, with a signiﬁcant
increase observed between both the high and very high versus low
dose groups (Fig. 6B). In accordance, a signiﬁcant positive correlation
was found between dose and maximal rostral–caudal migration at 2
DPT and 2 WPT (Fig. 6D–E). However, neither the quantitative nor theKinetics of migr
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gration were sustained at 16 WPT (Fig. 6C and F).
Based on the observed preferential rostral localization of donor cells in
the early post-transplantation period, we further assessed migration in
the parenchyma by speciﬁcally testing rostral versus caudalmigration rel-
ative to the injury epicenter. Therewas a signiﬁcant relationship between
dose and maximal caudal migration at 2 DPT (Fig. 6G), and maximal ros-
tral migration at 2 WPT (Fig. 6H). However, no correlative relationships
were observed at 16 WPT (Fig. 6I). Taken together, these data demon-
strate a dose dependent increase in the number of cells localized in the
caudal niche at 16 WPT, despite the fact that cells in the low dose group
were capable of comparablemaximalmigration in the injured spinal cord.ation distance 
 WPT 16 WPT
 WPT 16 WPTF
I
C
 WPT 16 WPT
10,000 15,000
-caudal migration (µm) 
p 0.05
0.05
0 5,000 10,000 15,000
Low
Medium
High
Very High
NS
Maximal rostral-caudal migration (µm)
00 400,000 600,000
Dose
.001
0 200,000 400,000 600,000
0
5,000
10,000
15,000
20,000
r=-0.11 NS
Dose
00 400,000 600,000
 Rostral        
 Caudal
r=0.75
NSr=0.47
Dose
p 0.005
0 200,000 400,000 600,000
0
5,000
10,000
15,000
20,000
       Max Rostral 
       Max Caudal
r=0.03
r=-0.15
NS
NS
Dose
in the injured spinal cord niche.Maximal rostral–caudalmigration of human SC121+ cells
9, respectively. Tukey's t-test p values are shown in the graph. Correlation analysis revealed
(E) 2WPT but not at (F) 16WPT; Pearson r=0.83, p ≤ 0.002; r=0.82, p ≤ 0.001; Pearson
tion distance in the rostral or caudal regions at (G) 2DPT; Pearson r=0.61, p ≤0.04, r=0.41,
3, p ≤ 0.88, r=−0.15, p ≤ 0.54. XY scatterplots of data points/group (dots shaded to indicate
n= 5 animals/group.
349K.M. Piltti et al. / Stem Cell Research 15 (2015) 341–3533.4. hCNS-SCns proliferation at 2 DPT and 2 WPT
We have previously demonstrated that hCNS-SCns proliferation
underlies donor cell expansion, that proliferation occurs in the early
post-transplantation period and is altered by the injured niche, and
that the proportion of human cells actively proliferating by 12 WPT
has declined to 1–2% (Sontag et al., 2014). Because low cell dose groups
exhibited greater expansion in the SCI niche, we tested the effect of cell
dose on hCNS-SCns proliferation using a cumulative BrdU labeling
paradigm. For this study, mice received i.p. injections of BrdU twice a
day beginning at the time of transplantation. BrdU incorporation was
found in both donor and endogenous cells as expected based on previ-
ous characterizations (McTigue et al., 2001); donor cells were therefore
identiﬁed by double labeling for SC121 and BrdU. At 2 DPT (Fig. S2A) or
2 WPT (Fig. 7A), the majority of the SC121+/BrdU+ cells were located
near the injection sites in all dose groups. At 2 WPT the total number
of SC121+/BrdU+ cells ranged from 2493 in the low dose group to
17,946 in the very high dose group, with a signiﬁcant increase detected
between these groups (Fig. 7B). These data suggest that the total number
of BrdU+ human cells increased with increasing cell dose.
However, evaluation of the effect of cell dose on the proportion of
human cells that exhibited BrdU incorporation revealed a more complex
relationship. At 2DPT the proportion of donor cells incorporating BrdU in
the injured niche was low (8%–2.9%) with no signiﬁcant difference
between the low and very high dose groups (Fig. S2B). In contrast, at 2
WPT, 84.2% of cells in the low dose group exhibited BrdU incorporation,
while only 41.7% of cells in the very high dose group did so (Fig. 7C),
and an inverse correlation was observed between the total number of
engrafted human cells and the proportion of SC121+/BrdU+ cells
(Fig. 7D). Alignment of spinal cord sections relative to the injury epicenter
revealed a preferential rostral localization of SC121+/BrdU+ cells at 2
WPT that was not affected by the total number of engrafted human
cells (Fig. 7E, Fig. S2C and Movies S5–6; Fig. 7F–H). These data suggest
the surprising ﬁnding that increasing dose exerted an inverse effect on
donor cell proliferation in the SCI microenvironment between 2 DPT
and 2 WPT, but do not support a regional speciﬁcity in proliferation
with respect to dose.3.5. hCNS-SCns proliferation 16 WPT
We investigated the relationship between transplantation dose and
markers associated with long-term donor cell proliferation at 16 WPT
using double labeling immunohistochemistry for SC121 and Ki67. As
shown in Fig. 8A, Ki76+ nuclei exhibited either solid nucleoplasmic or
dotted mid-G1 phase-like staining (Kill, 1996), both of which were in-
cluded in unbiased stereological quantiﬁcation. Labeling of endogenous
mouse cell nuclei was also observed. The estimated total number of
SC121+/Ki67+ cells ranged from 10,470 in the low dose group to
70,117 in the very high dose group, with a signiﬁcant increase in the
high and veryhigh dose groups (Fig. 8B) compared to the lowdose group.
The proportion of SC121+/Ki67+ cells ranged from 23.3% in the low
dose group to 16.5% in the very high dose group, with no signiﬁcant dif-
ference between the groups (Fig. 8C). However, as in the case of BrdU
analysis at early post-transplantation time points, there was an inverse
correlation between the total number of engrafted human cells and the
proportion of SC121+/Ki67+ cells (Fig. 8D), consistent with the in-
creased cell expansion observed in the low dose group. Further, align-
ment of spinal cord sections relative to the injury epicenter again
revealed a preferential rostral localization of SC121+/Ki67+ donor
cells rostral to the injury epicenter (Fig. 8E, Movies S7–8); however,
although there were no signiﬁcant overall differences between dose
groups (Fig. S2D), there was a speciﬁc and signiﬁcant inverse correla-
tion between the total number of engrafted human cells and rostral
localization of SC121+/Ki67+ cells (Fig. 8F–H). These data support a
sustained inverse effect of dose on donor cell proliferation in the SCImicroenvironment extending through 16WPT, and suggest that regional
differences in proliferation dynamics emerge over time.
Ki67 labeling detects cells in G1, S, G2 andM phase, and therefore can
signiﬁcantly overestimate the number of cells in activemitosis (Kill, 1996;
Tanaka et al., 2011). We therefore sought to determine what proportion
of Ki67+ cells were in active cell division using Phospho-Histone-3
(pH3), a speciﬁc M phase marker (Gurley et al., 1978; Shibata and Ajiro,
1993; Hendzel et al., 1997). Triple labeling immunohistochemistry for
SC121+/Ki67+/pH3+ cells (Fig. S3) demonstrated that the fraction of mi-
totic pH3+ cells within the SC121+/Ki67+ population ranged from 10.3%
in the low dose group to 4.8% in the very high dose group with no signif-
icant difference between the groups (1-way ANOVA p= 0.08). Propor-
tional analysis relative to the total number of SC121+ human cells
revealed that transplanted hCNS-SCns exhibited a mitotic index of 1–3%
at 16 WPT (depending on dose), consistent with previous observations
from our laboratory at a dose of 75,000 cells (Salazar et al., 2010; Sontag
et al., 2014).
4. Discussion
Cellular therapeuticsmay function via either replacement of a lost cell
population (e.g. generation of new dopamine neurons or myelinating
oligodendrocytes), restoration of a cellular function (e.g. synthesis/
secretion of an enzyme in the case of a genetic deﬁciency), or modula-
tion of the host microenvironment (e.g. attenuation of an autoimmune
response). Cell replacement/restoration requires long term functional in-
tegration of the donor cell population. However, the effect of transplant
dose on donor cell integration has been characterized only in hematopoi-
etic stem cells (HSC), where the magnitude of human HSC engraftment
and rate of donor cell mobilization is proportional to transplant dose
(Chen et al., 2004; Liu et al., 2010). However, donor-derived progeny in
peripheral blood increases over time irrespective of transplant dose
(Chen et al., 2004; Liu et al., 2010), indicating that the dynamics of
engraftment in the stem cell niche may be a key factor in successful cell
replacement. Additionally, HSC have been reported to fail multi-lineage
development when transplanted at ultra low density (Liu et al., 2010),
making assessment of dose-related integration into the niche an impor-
tant variable. In this regard, while it has generally been assumed that
“more is better”, the capacity of the injured CNS to provide integration
sites after therapeutic transplantation is unknown. Accordingly, we in-
vestigated relationship between the number of transplanted hCNS-SCns
(dose) and the spatiotemporal dynamics of early and long-term cell sur-
vival, proliferation, and migration in the SCI microenvironment.
Few previous studies have investigated the effect of unmodiﬁed
human neural stem cell/precursor dose in CNS injury or disease models.
A linear relationship between the number of transplanted human neural
precursors (200,000–2,000,000 cells) and graft volumewas reported in a
rat Parkinson's disease (PD)model (Ostenfeld et al., 2000), but not in a rat
stroke model, in which increasing hNSC dose (300,000–1,500,000 cells)
did not signiﬁcantly increase engraftment (Darsalia et al., 2011). The var-
iation in outcome between these studiesmay be due to differences in the
diseased versus injured niche, use of different transplantation paradigms,
and critically, differences inwhether adequate pharmacological immuno-
suppression was achieved in these respective xenotransplantation
models. In this regard, lack of adequate immunosuppression could lead
to a dose-dependent increase in immune rejection. In our study, similar
to HSC and the PD model above, increasing hCNS-SCns dose (10,000–
250,000 cells) exhibited a linear relationship with the total number
of engrafted donor cells, suggesting that human cell engraftment was
scalable within the SCI niche. However, the highest hCNS-SCns dose
(500,000 cells) exhibited a plateau in donor cell engraftment, suggesting
that the SCI niche does have a limit to its capacity to accommodate/
integrate donor cells. Because previous studies (Ostenfeld et al., 2000;
Keirstead et al., 2005; Rossi et al., 2010; Darsalia et al., 2011) have not
conducted complete analyses of cell engraftment, it is unclear whether
a similarly complex relationship encompassing both a linear increase in
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Fig. 7. Transplantation dose has an inverse effect on hCNS-SCns proliferation at 2 WPT. (A) An example of coronal spinal cord section immunostained for a human marker SC121 (blue
DAB) and BrdU (brown DAB) at 2 WPT. Photomicrograph of bilateral injection tracts (arrowheads), SC121+/BrdU+ cells (arrows), and an endogenous BrdU+ cell (asterisk). Inset scale
bar 10 μm. (B) The very high dose group showed signiﬁcantly greater estimated total number of SC121+/BrdU+ cells (colored bars shaded to indicate dose) when compared to low
dose group at 2WPT; mean± SEM, 1-way ANOVA p ≤ 0.05. Student's 2-tailed t-test p value is shown in the graph. Colored outlines of the initial number of SC121+ cells/group. However,
(C) normalization with the total number of human cells revealed that the low dose group exhibited a signiﬁcantly greater proportion of SC121+/BrdU+ cells when compared to the very
high dose group; mean ± SEM, 1-way ANOVA p ≤ 0.03. Tukey's t-test p value is shown in the graph. In accordance, correlation coefﬁcients revealed a signiﬁcant negative correlation be-
tweenhigher total number of SC121+ donor cells and greater proportion of SC121+/BrdU+ cells; Pearson r=−0.72, p ≤ 0.008. (E) 3D reconstruction of transplanted spinal cords showing
location of analyzed SC121+/BrdU+ cells (dots) in each dose group at 2WPT. The purple shaded area represents the lesion. Correlation analysis between transplant dose and proportion of
SC121+/BrdU+ cells localized in (F) the rostral region; Pearson r=−0.52, p ≤ 0.08; the epicenter (G); r=0.26, p ≤ 0.4, or (H) the caudal region; r=−0.28, p ≤ 0.38. XY scatterplots data
points/group (dots shaded to indicate dose) and regression line ± SEM. 2 WPT cohort n= 3 animals/group.
350 K.M. Piltti et al. / Stem Cell Research 15 (2015) 341–353engraftment with increasing cell dose and a plateau in this relationship
also exists in the injured/diseased brain as a transplantation niche.
Although only a small proportion of cells (9–29%) survived the
transplantation process, which is in accordance with our previous data(Sontag et al., 2014), there was no signiﬁcant relationship between
the proportion of dying cells and transplantation dose. The lack of
dose-related cell death may suggest that donor cell proliferation is reg-
ulated by cell density or density-dependent access to local nutrients and
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Fig. 8. Donor cells proliferation is dramatically decreased in the injured spinal cords between 2 WPT and 16 WPT. (A) An example of a coronal spinal cord section immunostained for
human marker SC121 (brown DAB) and Ki67 (blue DAB) at 16 WPT depicting human SC121+/Ki67+ cells (arrows) and an endogenous cell with a dotted G1 interphase stage-like
Ki67+ staining (asterisk). Inset scale bar 10 μm. (B) Very high and high dose groups exhibited signiﬁcantly greater estimated total number of SC121+/Ki67+ human cells (colored bars
shaded to indicate dose) compared to the low dose groups; mean ± SEM, 1-way ANOVA p = 0.0004. Tukey's t-test p values are shown in the graph. Colored outlines of the initial
dose of SC121+ cells. (C) No difference was found between the proportion of SC121+/Ki67+ cells in each dose group after normalization to the total number of SC121+ cells (previously
published in Piltti et al., submitted for publication);mean± SEM, 1-way ANOVA p=0.28. However, (D) correlation analysis revealed a signiﬁcant negative relationship between increas-
ing cell dose and the proportion of SC121+/Ki67+ donor cells; Pearson r=−0.55, p ≤ 0.01. (E) 3D reconstruction of transplanted spinal cords showing location of analyzed SC121+/Ki67+
cells (dots) at 16WPT. urple shaded area represents the lesion. (F) Correlation analysis between transplant dose and proportion of SC121+/Ki67+ cells localized in (F) the rostral region;
Pearson r=−0.63, p ≤ 0.003; (G) the epicenter; r=−0.3, p ≤ 0.2, or (H) the caudal region; r= 0.34, p ≤ 0.1. XY scatterblots data points/group (dots shaded to indicate dose) and re-
gression line ± SEM. 16 WPT cohort n= 5 animals/group.
351K.M. Piltti et al. / Stem Cell Research 15 (2015) 341–353growth factors/signals (Discher et al., 2009; Gomer et al., 2011; Brizzi
et al., 2012). In this context, inclusion of a transplantation matrix or ex-
ogenous growth factors might enhance donor cell engraftment after
epicenter transplantation (Lu et al., 2014), although few studies have di-
rectly evaluated this issue, and the effect of trophic factors axon exten-
sion appears to be greater than that on overall neural progenitor
engraftment (Bonner et al., 2011). In contrast, there was a signiﬁcantinverse correlation between donor cell proliferation/expansion and
transplantation dose. A similar inverse dose effect on donor cell prolifer-
ation using Ki67 antibody was reported by Ostenfeld et al. for PD at 2
WPT, but not by Darsalia et al. for stroke. In the immunodeﬁcient SCI
niche, donor cell expansion ranged from 16.3 fold (low dose) to 9.6 fold
(very high dose) when normalized relative to the number of surviving
cells at 2 WPT. Importantly, while these data represent signiﬁcant cell
352 K.M. Piltti et al. / Stem Cell Research 15 (2015) 341–353expansion, we calculate that as few as four divisions of each surviving
human cell at 2WPTwould be sufﬁcient to result in the numbers detect-
ed at 16 WPT (see Fig. 4B). Regardless of transplant dose, however, only
1–3% of the hCNS-SCns remainedmitotic (that is, in M phase as detected
by pH3) at 16WPT, which is consistent with previous observations from
our laboratory (Salazar et al., 2010) and others (Ostenfeld et al., 2000;
Darsalia et al., 2011). Nonetheless, a critical remaining question iswheth-
er donor cell expansion dynamics involve a high degree of proliferation
by a small number of human cells, or a ﬁxed number of divisions by
each engrafted donor cell. Understanding this dynamic relationship
may reveal additional insight into the intrinsic and extrinsic factors deﬁn-
ing donor cell proliferation and engraftment, and could inform strategies
to improve the safety of cell therapeutics.
In accordance with our previous observations (Salazar et al., 2010),
hCSN-SCns transplanted at the early-chronic stage of SCI exhibited
migration away from the injury epicenter, as well as a preferential
rostral localization in migration and proliferation. These data may
suggest that extrinsic factors in the microenvironment inﬂuence the
spatiotemporal dynamics of donor cell engraftment. Cell death induced
neuroinﬂammation causes local upregulation of cytokines and chemo-
kines, such as IL-8, SDF-1a, TNF-a aswell as extracellularmatrix proteins
such as chondroitin sulfate proteoglygans (CSPGs) and integrins,
which are crucial for guiding precursor migration and repair process
(Leone et al., 2005; Connor et al., 2011; Brizzi et al., 2012; Dyck and
Karimi-Abdolrezaee, 2015; Fawcett, 2015; North et al., 2015). In parallel,
SCI results in a time-dependent regulation of the expression of trophic
and regulatory factors such as ciliary neurotrophic factor (CNTF), FGF2,
and glial growth factor 2 (GGF2), which can stimulate proliferation of en-
dogenous precursor cells (Zai et al., 2005; Kumamaru et al., 2013). Inter-
estingly, the highest FGF2 and GGF2 levels, and greatest chronic cell
death, after SCI have been reported rostral to the epicenter (Shuman
et al., 1997; Warden et al., 2001; Zai et al., 2005), perhaps suggesting
that other ongoing injury dynamics could derive selective donor cell re-
cruitment in a spatially dependent manner. Interestingly, increasing
transplantation dose increased the number of donor cells localized in
the caudal niche at 16 WPT, perhaps suggesting that donor cell density
may in turn modulate SCI microenvironment by producing factors that
stimulatemigration of their sister cells, resulting in an increase in the dis-
tribution of donor cells throughout the tissue. Alternatively, as perhaps
suggested by the plateau observed in hCNS-SCns engraftment, the num-
ber of integration sites adjacent to the injury and transplantation locus
could have a limit, resulting in increased migration to distal regions
once these closer sites are ﬁlled.
5. Conclusions
All together, these data suggest that the SCI nichemay have a limited
capacity to provide integration sites/growth signals for donor cells that
can be detected as a change in dynamics of donor cell engraftment, ex-
pansion andmigration. Critically, donor cell expansionwas inversely reg-
ulated by target niche parameters and/or the initial donor cell density,
highlighting that the response of transplanted cells to the hostmicroenvi-
ronment should be a key variable in deﬁning target dosing in pre-clinical
models of CNS disease and injury.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2015.07.001.
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